Neoadjuvant anthracycline and trastuzumab for breast cancer: Is concurrent treatment safe?

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 209-211

  Bozovic Spasojevic, Ivana ^a   Azim, Hatem A ^a   Paesmans, Marianne ^a   Suter, Thomas ^b   Piccart, Martine J ^a   de Azambuja, Evandro ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LETTER; MYOCARDIAL DISEASE; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SURVIVAL TIME; TREATMENT RESPONSE;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 79952043612     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70013-4     Document Type: Letter

References (10)

1. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100:14-20.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
5. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
6. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
7. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
8. Peto R Clinical trial methodology. Biomedicine 1978, 28:24-36.
9. Zuppinger C, Timolati F, Suter TM Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007, 7:61-66.
10. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004, 279:8290-8299.